Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

About a year after investing in Vigil Neuroscience Inc., Sanofi is now acquiring the Watertown biotech and its treatment in ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

Sanofi to acquire clinical-stage biotechnology company, Vigil Neuroscience for $470 million: Paris Friday, May 23, 2025, 11:00 Hrs [IST] Sanofi, an innovative global healthcare co ...

French pharma Sanofi has acquired the U.S.-based biotech firm Vigil Neuroscience for $470 million, aiming to bolster its ...

Sanofi SA made good on its plan to bear down on M&A by agreeing to buy Vigil Neuroscience Inc. for $8 per share (NASDAQ:VIGL). Included in the transaction is a non-tradeable contingent value right ...

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

While Vigil stock rocketed upward on the news, Sanofi shares dipped slightly in midday trading, reflecting investor caution ...

Part of the deal also includes an additional $2 cash payment per share upon the first commercial sale of Vigil’s Alzheimer’s ...

SANOFI will acquire Vigil Neuroscience, a clinical-stage biotech company in a $470-million deal, the companies said on Thursday, as the French drugmaker seeks to boost its neurological pipeline ...

Vigil Neuroscience shares jumped nearly 250% Thursday after the Alzheimer's disease drug developer reached a deal to be ...

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K. regulators cleared Sarepta to restart an Elevidys study and Altos Labs ...